Aim: Direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection have a significantly high sustained virologic response rate after a short treatment course and do not have any severe adverse effects. Patient-reported outcomes (PROs) have become increasingly important to assess the total impact of a chronic disease. We aimed to evaluate the changes in symptoms of patients with HCV infection treated with DAAs by using PROs.
INTRODUCTION

D IRECT-ACTING ANTIVIRALS (DAAS) have changed the treatment of hepatitis C virus (HCV) infection.
Daclatasvir/asunaprevir (DCV/ASV) 1 and sofosbuvir/ ledipasvir (SOF/LDV) 2 for HCV 1B infection and sofosbuvir/ribavirin (SOF/RBV) for HCV 2A/2B infection 3 are common DAA treatments in Japan. These treatments have significantly high sustained virologic response (SVR) rates (85-100%) after a short treatment course (12-24 weeks) and do not have any severe adverse effects.
Patient-reported outcomes (PROs), including healthrelated quality of life (QOL), have become increasingly important to assess the total impact of a chronic disease or an intervention on patient health and well-being. 4 Interferon-based HCV treatment leads to lower QOL (as measured by the short form 36-item ) in the period of treatment but it recovers to pretreatment levels 12 weeks later, whereas DAA treatment does not decrease QOL scores in the period of treatment and it remains the same at the start of treatment and 12 weeks after discontinuation of treatment. 5 Interestingly, QOL is impaired in patients with viral clearance after interferon but not after spontaneous clearance. 6 However, various PROs, such as the HCV-specific Quality of Life Chronic Liver Disease Questionnaire -HCV version, Functional Assessment of Chronic Illness Therapy -Fatigue, and Work Productivity and Activity Index have improved scores 12 weeks after patients discontinue treatment with DAAs. 7 Different PROs measure different factors. Therefore, PRO instruments that specifically capture the effect of HCV infection on QOL will be needed in the new treatment era. 8 We have reported several PROs related to chronic liver disease. The cirrhosis-related symptom score (CSS), used for total evaluation of chronic liver disease, is correlated with the Child-Pugh score and minimal hepatic encephalopathy. 9 The restless legs syndrome (RLS) is a common complication of cirrhosis and affects sleep status as evaluated by the Pittsburg sleep quality index (PSQI), and QOL is evaluated by the SF-36. 10 The Epworth sleepiness scale (ESS) in patients with cirrhosis can be improved by ingestion of branched chain amino acid supplements. 11 Previously, we used these PROs and could evaluate changes in symptoms in response to liver transplantation and supplementation. 12 To evaluate the changes in symptoms of patients treated with DAAs, we used these PROs in this study. Additionally, for evaluation of psychological distress, we added the Kessler 6 score (K-6) 13 to this PRO set.
METHODS
Patients
O
NE HUNDRED AND seven patients with chronic infection with HCV genotype 1B, 2A, or 2B with chronic hepatitis and compensatory cirrhosis were treated with DAAs, DCV/ASV (Bristol-Myers Squibb, Tokyo, Japan) or SOF/LDV (Gilead Sciences, Tokyo, Japan) for 1B, and SOF/RBV for 2A/2B (Chugai Pharmaceutical Co., Tokyo, Japan), at Nagasaki Harbor Medical Center (Nagasaki, Japan) from June 2014 to November 2016. Combination therapy with DCV/ASV was given orally for 24 weeks 1 and SOF/LDV and SOF/RBV were given orally for 12 weeks. 2, 3 During the treatment period, serum HCV-RNA was examined every 4 weeks; after the end of the treatment period, these measurements were carried out every 12 weeks. Sustained virologic response was determined at 24 weeks after the end of treatment. At week 24 after the end of treatment, an SVR was achieved in all patients.
Patient-reported outcomes were evaluated at the start of treatment and 1 year after the start of treatment. At the start of treatment, patients were asked about their use of medications for abnormal lipids, hypertension, diabetes, and gout. Informed consent was obtained from each patient included in the study, and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as evidenced by the approval of the study by the Human Research Ethics Committee of Nagasaki Harbor Medical Center (NIRB 1512003).
Patient-reported outcomes
The CSS questionnaire contains items regarding cirrhotic symptoms, which include hand tremors (CSS1), appetite loss (CSS2), foot muscle cramps (CSS3), fatigue (CSS4), decreased strength (CSS5), anxiety (CSS6), abdominal fullness (CSS7), abdominal pain (CSS8), and a feeling of low energy (CSS9). An "impact factor" for each item was calculated, which was defined as the product of the frequency of the item and the mean importance that the patients attributed to the item. The impact factor for each item ranged from 0 to 3, and the CSS was calculated as the sum of the impact factors. 9, 11, 12 The ESS 14 was used to evaluate daytime hypersomnolence; ESS scores range from 0 to 24, and a score of ≥10 indicates significant daytime hypersomnolence. Sleep quality was evaluated using the Japanese version of the PSQI. 15, 16 Responses to the PSQI questionnaire were used to generate seven components, which were scored from 0 (normal) to 3 (extremely poor). Health-related QOL was evaluated using the Japanese SF ). This tool contains one item that evaluates the perceived change in health status, and the remaining 35 items are used to generate eight subscales of 0-100 that evaluate physical functioning, role limitations due to poor physical health, bodily pain, general health perception, vitality, social functioning, role limitations because of poor emotional health, and role limitations because of poor mental health. All of the patients were evaluated for the presence of RLS using a written survey that was developed by the International Restless Legs Syndrome Research Group in 2003. Patients were diagnosed with RLS if they fulfilled all four criteria and showed symptoms of RLS that occurred at least twice per week. The six-item K-6 score was used to evaluate psychological distress. The K-6 is scored from 0 to 24, with a score of 13 or greater categorized as the patient experiencing psychological distress. 17 
Laboratory measurements
Laboratory data and anthropometric measurements were obtained for each subject every 4 weeks during treatment and every 12 weeks after treatment. The body mass index of each patient was calculated from their weight in HCV symptoms after antivirals E233 Hepatology Research 2018; 48: E232-E239 kilograms divided by the square of their height in meters. Laboratory examinations included assessment of the white blood cell count, platelet count, prothrombin time, hemoglobin, C-reactive protein, blood urea nitrogen, creatinine, total protein, albumin, total bilirubin, alanine aminotransferase, γ-glutamyl transpeptidase, cholinesterase, triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol (LDL), fasting plasma glucose, and hemoglobin (HbA1c).
Statistical analysis
Data were analyzed using StatView 5.0 software (SAS Institute, Cary, NC, USA). Laboratory result variables were compared using correlation analysis, t-tests, and χ 2 -tests. Correlations were evaluated with coefficients of correlation. Multivariate analysis was carried out with logistic regression tests. Values of P < 0.05 were considered statistically significant.
RESULTS
C
LINICAL PROFILES AT the start of DAA treatment were generally not different among groups (Table 1 ). The mean age of the patients treated with SOF/RBV was lower than that of patients in other groups and serum albumin concentration in the group treated with DCV/ASV was lower than that in the SOF/LDV group. Platelet counts in the DCV/ASV group were higher than the other groups. However, other clinical factors, including medication use, were not different among groups.
Changes in symptoms evaluated by PROs from the start of DAA treatment to 1 year after treatment are summarized in Table 2 . The total CSS is summed from CSS1 to CSS9. The CSS items 3-9 and total CSS were improved at 1 year of follow-up. Similarly, K-6 and PSQI were also improved at 1 year. Thus, liver disease-related symptoms (CSS), psychological distress (K-6), and sleep disturbances (PSQI) improved in the 1 year after treatment with DAAs. /μL; low-density lipoprotein (LDL), 70-139 mg/dL; high-density lipoprotein (HDL), M, 40-86 mg/dL; HDL, F, 40-96 mg/dL; triglyceride (TG), 50-149 mg/dL; creatinine, M, 0.61-1.04 mg/dL; creatinine, F, 0.47-0.79 mg/dL; ferritin, M, 39.4-340 ng/mL; ferritin, F, 3.6-114 ng/mL; and hemoglobin (HbA1c), 4.6-6.2%; α-fetoprotein (AFP), not over 10.0ng/mL. All laboratory data measurements were undertaken after overnight fasting. No significant differences were found between the no change and upregulation groups. *Significant difference between daclatasvir/asunaprevir (DCV/ASV) and sofosbuvir/ledipasvir (SOF/LDV). **Significant difference between DCV/ASV and SOF/ribavirin (RBV). ***Significant difference between SOF/LDV and SOF/RBV. AFP, α-fetoprotein; BW, body weight; CH, chronic hepatitis; DM, diabetes mellitus; HT, hypertension; LC, liver cirrhosis; NS, not significant.
For each PRO, a sick status was defined as more severely affected patients. A poor sleeper had 10 or more points on the ESS and 6 or more points on the PSQI. We have previously shown that minimal hepatic encephalopathy is correlated with 9 or more points on the CSS. 9 Psychological distress is defined as 13 points or more on the K-6. The presence of RLS was defined by RLS criteria. In the 107 patients, poor sleepers, minimal hepatic encephalopathy, psychological distress, and RLS were improved from the start of DAAs to 1 year after (Table 3) . However, QOL, evaluated by the SF-36, was not different at the 1-year follow up (Table 4) .
Next, we paid attention to changes in total CSS. Scores at 1 year were subtracted from the score at the start of DAA treatment to obtain the change in CSS. Several clinical factors correlated with changes in total CSS were found (Fig. 1) . Among lifestyle-related diseases, hypertension medication users showed greater improvement than non-users (Fig. 1a) . Serum LDL levels at the start of DAA treatment were higher in patients with worsening CSS scores than in the CSS recovery group (Fig. 1b) . Patients carrying the HCV genotype 2B had a lower incidence of recovery than those with 1B or 2A (Fig. 1c) , but the type of DAA was not related to changes in total CSS (Fig. 1d) . Poor sleepers by ESS at the start of DAA had greater improvements in total CSS score than normal sleepers (Fig. 1e) , and those with RLS at 1 year had worse CSS scores (Fig. 1f) . Women experienced greater improvements in CSS than men (Fig. 1g) . The other clinical factors in our study were not related to changes in total CSS at 1 year.
We also evaluated factors correlated with CSS deterioration (Table 5a ) and improvement (Table 5b ). Candidate factors were selected from the previous analysis: HCV genotype 1B or 2A (non-2B), non-hypertension drug users (HTÀ), serum LDL levels at the start of DAA (LDL0), male sex, ESS scores at the start of DAA treatment (ESS0), and RLS at 1 year (RLS1Y). The factors that contributed to CSS worsening were HCV genotype 2B and RLS at 1 year, but we did not detect any factors correlated with CSS improvement.
DISCUSSION
I N THIS STUDY, liver-related symptoms, sleep disturbance, psychological distress, and RLS in patients with HCV infection treated with DAAs were improved 1 year Change in scores of 1 unit or more was defined as CSS recovery; other patients were included in the CSS worsening group. CSS worsening group had a lower value of low-density lipoprotein (LDL) at the start of DAA treatment (P = 0.047). Y-axis represents value of serum LDL (mg/dL). (c,d) Patients with HCV genotype 2B were more likely to worsen than 1B and 2A (P = 0.0313 between 1B and 2B; P = 0.0321 between 2A and 2B) (c), but CSS changes did not differ by type of DAA treatment (d). ASV, asunaprevir; DCV, daclatasvir; LDV, ledipasvir; RBV, ribavirin; SOF, sofosbuvir. (e,f) Poor sleepers as defined by the Epworth sleepiness scale (ESS0) at the start of DAA experienced recovery (P = 0.03) (e), but those with restless leg syndrome at 1 year (RLS1Y) worsened (P = 0.0202) (f). (g) Female patients were more likely to recover than male patients (P = 0.0244). Error bars represent standard deviation. Differences between groups were evaluated by a t-test. P-values <0.05 were considered statistically significant.
after beginning treatment. However, QOL did not recover. Changes in total CSS were correlated with HCV genotype, sex, hypertension drug use, elevated serum LDL at the start of treatment, poor sleeper at the start of treatment, and RLS 1 year after the start of treatment. Factors contributing to CSS worsening were HCV genotype 2B and RLS at 1 year. Our patients experienced improvements in symptomrelated scores but did not experience changes on the SF-36 score from the start of DAA treatment to 1 year after. It has been previously reported that SF-36 scores were not improved by interferon or DAA. [4] [5] [6] [7] However, patients with spontaneous clearance of HCV infection have shown improved SF-36 scores 6, 18 and patients with treatment eradication of HCV also show improved SF-36 scores. 19 In contrast with our study, Younossi et al. 5 reported that the general health domain of the SF-36 improved during DAA treatment, and the body pain domain improved at 12 weeks after cessation of treatment. In our study, the patients were older (Table 1) than those in reports with improved SF-36 scores. 5, 6, 18 We speculated that the high age of the patients influenced the improvement in SF-36 score by DAA treatment. Changes in SF-36 induced by treatment were primarily evaluated only 12 weeks after the end of treatment. 4, 5, 7 We speculated that the patients were evaluated by the SF-36 several years after spontaneous clearance. Treatment with DAAs induced improvement of HCV infection-related symptoms, including foot muscle cramps, fatigue, decreased strength, anxiety, abdominal fullness, abdominal pain, a feeling of low energy, sleep disturbance, psychological distress, and RLS, but it may require several years after relief from these symptoms for an effect on QOL to become apparent. In a future study, patients in whom HCV was eradicated should be observed carefully for QOL and other symptoms, and those who did not recover after DAA should also be evaluated at longer follow-up times.
It is clear from our study that daytime somnolence and sleep disturbances in patients with HCV infection were ameliorated by DAA treatment. A previous report revealed that the PSQI score improved during DAA treatment. 20 Restless leg syndrome also causes sleep disturbances. The overall prevalence of RLS among inhabitants of Ajimu in Japan aged ≥65 years is 0.96% and the prevalence of RLS is lower in Japan than in studies of European and North American populations. 21 Previously, we reported that 25 of 149 patients with chronic liver disease (16.8%) fulfilled the diagnostic criteria for RLS. 10 The frequency of HCV infection and interferon treatment that were correlated with RLS onset 22, 23 were also not significantly different between the RLS and non-RLS groups. 10 Patients with RLS often recovered after DAA treatment, but patients who did not recover from RLS did not experience improvements in their CSS score. We think that patients with HCV infection should have more attention paid to RLS and treatment for RLS after HCV clearance by DAAs may be effective in making changes in CSS.
In our study, several problems with extrahepatic symptoms have been clarified. In previous studies, QOL in HCV-infected patients has been shown to be correlated with underlying comorbidities, income, and marital status and is not correlated with stage. 19, 24 Because a sex difference was found in changes in CSS, social background factors should also be evaluated. In this study, the underlying comorbidities (abnormal lipid levels, hypertension, diabetes, and gout) were not related to the change in SF-36 score or CSS. Hepatitis C virus genotype 2B was found to be a contributing factor for CSS worsening. However, differences in symptoms by HCV genotype have not been fully evaluated in previous studies. The stage of liver fibrosis and the infecting genotype are not commonly associated with neurocognitive alterations in HCV infection. 25 However, it has been reported recently that patients infected with HCV genotype 3 are at higher risk for end-stage liver disease, hepatomas, and liver-related death. 26 Thus, differences in genotypes should also be considered when evaluating symptoms.
Additionally, HCV-related encephalopathy is not correlated with viral status but is correlated with cognitive dysfunction 27 and sleep disturbance. 28 Because poor sleepers after SVR are at risk of HCV-related encephalopathy, HCV-cleared patients should be followed up.
Serum LDL at the start of DAA treatment is also correlated with changes in CSS. Low-density lipoprotein may affect HCV-RNA replication, 29 dietary cholesterol intake is associated with progression of liver disease in patients with HCV infection, 30 and the APOE-ε4 allele is protective against attention deficit in HCV-infected individuals. 31 Thus, a full explanation of the relationship between lipids and CSS is still lacking. Direct-acting antiviral treatment cleared HCV-RNA in patients, but symptoms and QOL did not fully recover in patients with elevated LDL at baseline. For amelioration of QOL, lingering HCV-related symptoms should be explored. The limitations of our study were the small sample size, single-institution data, and 1-year observation period. These limitations should be considered in future studies.
